Pharmaceutical Archives

Safely navigating through a crisis

2020 will go down as one of the most difficult for companies and leaders around the world. The corona virus has taken lives, isolated families, closed airports and put a fear into many like never before. Whilst most of us have had the privilege of a stable life occupied with routine, the future is now filled with uncertainty and disruption. As our new normal evolves, some organizations will be strong enough to survive, but a great number will fold. Leaders have never been more challenged to guide their teams through [...]

By optalert|2020-05-26T15:31:20+10:00May 25th, 2020|Automotive, Goods & Passenger Transport, Mining, Neurology, Pharmaceutical|

What is the Optalert JDS™ and why is it leading the drowsiness monitoring field?

Optalert’s sophisticated software algorithm, leads the drowsiness monitoring field, by providing the next level layer within driver monitoring systems (DMS). Optalert’s scientifically validated Johns Drowsiness Scale (JDSTM) enables an objective, real time, quantifiable measure of drowsiness. Applicable across ethnicity, gender and age, the JDS™ empowers the driver with the ability to avoid dangerous microsleeps. Providing a continuous numerical score of the driver’s impairment, the system not only cautions the driver, but it also informs the vehicle, with early prediction of drowsiness. Drowsy drivers display certain driving behaviour as their ability [...]

By optalert|2020-02-26T22:07:27+11:00February 26th, 2020|Pharmaceutical|

Could blinks be the answer to Alzheimer’s disease?

September is World Alzheimer’s month, the international campaign which raises awareness and challenges the stigma that surrounds dementia. Around the world 50 million people have dementia, and each year there are nearly 10 million new cases. The total number of people with dementia is projected to reach 82 million by 2030! With over 100 forms of dementia, the most well-known form is Alzheimer’s disease (AD), which accounts for 50-60% of all cases. Although a widespread condition, diagnosis and treatment of AD today is inadequate. Often multiple tests including patient history, [...]

By optalert|2019-09-03T16:23:57+10:00September 3rd, 2019|Neurology, Pharmaceutical|

BIO2019 Philadelphia – It Starts with One!

BIO International Convention is back in Philadelphia, June 3-6, to celebrate the globally important innovations in biotech that start with one: one meeting, one theory, one trial, one breakthrough. Optalert look forward to joining the global biotech community during partnering sessions and will be available for meetings through the official Bio2019 partnering portal, opening 2nd April 2019. Optalert will present their latest scientific technology for the objective measurement of drowsiness, which is also being used in pharmaceutical drug trials and neurological research studies in the fields of Epilepsy, Traumatic Brain [...]

By optalert|2019-03-29T16:35:34+11:00March 29th, 2019|Pharmaceutical|

Las Vegas CES2019 Highlights

The Consumer Electronics Show (CES2019) dazzled participants once again with glimpses of technologies and products on the horizon for the future. With over 180,000 attendees from 150 different countries, circulating over 11 venues throughout Las Vegas. Optalert’s key conversations at this year’s event included autonomous vehicles, enhanced ‘early warning’ drowsiness and distraction features, and AI assisting in remote healthcare technology. Optalert’s Chief Technical Officer Simon Block, shares some of his top highlights for the show: 1. Automotive Innovation Intelligent cars dominated the conversation in the automotive market, with seamless connectivity critical [...]

By optalert|2019-01-17T14:05:06+11:00January 17th, 2019|Automotive, Pharmaceutical|

Introducing the BlinQ system by Optalert

Optalert is pleased to introduce the BlinQ system for the measurement of drowsiness or wakefulness in clinical trials. Optalert uses advanced patented algorithms to determine the exact drowsiness or wakefulness of a subject. By applying Artificial Intelligence techniques and machine learning Optalert has been able to objectively quantify drowsiness or wakefulness. Utilising the Johns Drowsiness Scale (JDS), Optalert's future-proofed approach can advance clinical drug trial timelines and deliver new therapies to market faster. Current methodologies for measuring drowsiness or wakefulness are used across a wide range of clinical drug trials including anti-depressants, shift-work disorder, narcolepsy [...]

By optalert|2018-12-17T15:50:16+11:00December 17th, 2018|Pharmaceutical|

Challenges of pharmaceutical companies

Pharmaceutical companies face many challenges, with hundreds of new drugs required to transition through clinical trial phases, regulatory processes and to market, more quickly and more efficiently. The Centre for the Study of Drug Development (CSDD) estimates the cost of developing a prescription drug that gains market approval at $2.6 billion. Even more remarkable is that 90% of medicines that start being tested in people don’t reach the market because they are unsafe or ineffective. “May cause drowsiness” This is a common warning label on [...]

By optalert|2018-11-08T10:52:12+11:00November 2nd, 2018|Pharmaceutical|

5 of the greatest technological discoveries in the medical field

Every technological discovery aims to improve our health, safety, and quality of life. Every day, we marvel over exciting new developments that emerge from each corner of the globe. A few weeks ago, we looked at seven of the most significant pharmacological discoveries, and this week, we want to expand our exploration into great technology that help diagnose or treat disease and improve health. As we find ourselves increasingly immersed in advanced digital technology, we’re introduced to new discoveries that sound almost as if they came straight out of a [...]

By optalert|2018-10-11T13:08:24+11:00October 10th, 2018|Pharmaceutical|

From ESS to the JDS: Dr Murray Johns’ drowsiness detection technology enters the pharmaceutical industry

Optalert revolutionises pharmaceutical research with in-clinic test for wakefulness. Richmond, VIC: Optalert is pleased to introduce its latest wakefulness detection technology to the pharmaceutical industry for use during clinical drug trials. Optalert’s technology enhances clinical testing by offering pharmaceutical researchers an objective, measurable and real-time scale of drowsiness in addition to the alternative wakefulness, common outcomes and/or side effects measured in pharmaceutical drug trials. A highly sensitive LED fitted in Optalert’s glasses tracks eyelid movement, speed and blink frequency at a rate of 500 times per second. Results are then [...]

By optalert|2019-10-15T10:46:01+11:00September 11th, 2018|Pharmaceutical|

What’s involved in a pharmaceutical trial?

It is estimated global pharmaceutical company Johnson and Johnson employs more than 127,000 people. And in the US alone more than 800,000 people work in the pharmaceutical industry developing, testing, and producing drugs for a range of medical ailments. From vaccinations and Insulin to contraception, each medication must face scrutiny and assessment through vigilant testing and trials. Side effects and health risks are assessed through various trial stages. Once a drug is approved for use, it is then marketed and sold. Fast facts about the pharmaceutical industry The industry achieved [...]

By optalert|2018-10-11T13:06:11+11:00August 19th, 2018|Pharmaceutical|